Analyst Consensus ?
ConsensusBuy15 ratings
Bullish1280.0%
Neutral213.3%
Bearish16.7%
West Pharmaceutical Services, Inc. · WST · FY2026 Q1 · Calendar Q2 2026
West Pharma raises guidance as GLP-1 and Annex 1 drive growth
The quarter supports a constructive view of West Pharma's growth trajectory: demand for GLP-1-related components, biologics and Annex 1 upgrades drove a guidance increase. The next test is whether capacity expansion and operational improvements can sustain growth and margins as commodity and regulatory risks persist.
Reported Before market openNYSEHealthcare
$26.46B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$2.13
Consensus $1.68
EPS surprise
+26.8%
Reported versus consensus
Reported revenue
$844.9M
Consensus $780.3M
Revenue surprise
+8.3%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+12.9%
Event window
SPY move
-0.4%
Same window
Abnormal move
+13.2%
Stock minus SPY
Volume
3.3×
Versus trailing sessions
Subsequent drift
+2.1%
Up to 20 sessions
WSTSPY benchmark
Ask FN2 about WST FY2026 Q1
Transcript, numbers and history already loaded
Why did WST rise 12.9% after beating EPS estimates in FY2026 Q1?What changed in WST's guidance and outlook in FY2026 Q1?Give me the bull and bear case for WST after FY2026 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
West Pharma moved from maintained guidance in the prior quarter to raised full-year guidance. The current analysis also highlights a fully operational Dublin West Vantage site, a $1 billion share-repurchase authorization, and an expected 200-basis-point revenue contribution from Annex 1 and HVP conversion initiatives.
Guidance delta
Management raised full-year guidance to 7%-9% organic revenue growth and adjusted EPS of $8.40-$8.75, from the prior quarter's 5%-7% organic growth and approximately 10% EPS-growth outlook.
Key takeaways
- Q1 results beat expectations, with growth led by HVP components, particularly GLP-1 elastomers.
- Annex 1 upgrades, biologics demand, and the Dublin site support the capacity and growth plan.
- Operational excellence is being extended across European and U.S. sites, while execution and commodity risks remain.
Management priorities
- Scale Dublin drug-handling capacity and broader contract manufacturing.
- Advance Annex 1 conversion projects and HVP component upgrades.
- Extend operational excellence, develop delivery devices, and expand in Asia Pacific.
Follow WST with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$374.11Current
$295Low
$369.14Average
$447High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 24, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Morgan Stanley | Overweight | Equal Weight | Upgrade | Sep 22, 2026 |
| UBS | Buy | Buy | Maintain | Sep 9, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 3, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 27, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Jul 2, 2026 |
| Barclays | Overweight | Equal Weight | Upgrade | Jun 9, 2026 |
| Stephens & Co. | Overweight | Overweight | Maintain | Jun 2, 2026 |
| B of A Securities | Buy | Buy | Maintain | Dec 13, 2024 |
| Jefferies | Buy | Hold | Upgrade | Feb 7, 2024 |
| Deutsche Bank | Hold | Hold | Maintain | Dec 14, 2022 |
| Bank of America | Underperform | Neutral | Downgrade | Dec 12, 2019 |
| William Blair | Outperform | Outperform | Maintain | Apr 23, 2019 |
| Goldman Sachs | Neutral | Neutral | Maintain | Jan 24, 2018 |
| Wells Fargo | Outperform | Outperform | Maintain | Oct 27, 2017 |
| Janney Capital | Buy | Buy | Maintain | Jan 8, 2016 |
Named analyst price targets
Upside is calculated against the persisted current price $374.11. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Morgan Stanley | Kallum Titchmarsh | $400 | $361.73 | +6.9% | Sep 22, 2026 |
| UBS | Analyst unavailable | $415 | $338.06 | +10.9% | Sep 9, 2026 |
| Evercore ISI | Analyst unavailable | $425 | $333.12 | +13.6% | Jul 27, 2026 |
| BNP Paribas | Analyst unavailable | $447 | $353.71 | +19.5% | Jul 13, 2026 |
| Morgan Stanley | Analyst unavailable | $365 | $353.68 | -2.4% | Jul 9, 2026 |
| Evercore ISI | Daniel Markowitz | $410 | $359.27 | +9.6% | Jul 6, 2026 |
| KeyBanc | Analyst unavailable | $390 | $365 | +4.2% | Jul 2, 2026 |
| Barclays | Luke Sergott | $400 | $319.75 | +6.9% | Jun 9, 2026 |
| Morgan Stanley | Analyst unavailable | $315 | $306.39 | -15.8% | Apr 27, 2026 |
| Barclays | Analyst unavailable | $310 | $306.16 | -17.1% | Apr 27, 2026 |
| UBS | Dan Leonard | $340 | $246.6 | -9.1% | Feb 13, 2026 |
| Deutsche Bank | Analyst unavailable | $315 | $247.49 | -15.8% | Feb 13, 2026 |
| Barclays | Luke Sergott | $265 | $243.61 | -29.2% | Feb 13, 2026 |
| Jefferies | David Windley | $295 | $249.97 | -21.1% | Feb 10, 2026 |
| Evercore ISI | Daniel Markowitz | $320 | $237.88 | -14.5% | Feb 3, 2026 |
| Morgan Stanley | Analyst unavailable | $285 | $274.14 | -23.8% | Dec 1, 2025 |
| Barclays | Analyst unavailable | $325 | $293.62 | -13.1% | Oct 27, 2025 |
| UBS | Dan Leonard | $355 | $307.25 | -5.1% | Oct 24, 2025 |
| Deutsche Bank | Justin Bowers | $345 | $304.74 | -7.8% | Oct 24, 2025 |
| Evercore ISI | Daniel Markowitz | $390 | $309.28 | +4.2% | Oct 23, 2025 |
| Evercore ISI | Analyst unavailable | $350 | $268.07 | -6.4% | Oct 7, 2025 |
| Barclays | Analyst unavailable | $275 | $271.42 | -26.5% | Oct 2, 2025 |
| Redburn Partners | Jamie Clark | $311 | $257.53 | -16.9% | Sep 15, 2025 |
| Barclays | Luke Sergott | $245 | $222.68 | -34.5% | Jun 24, 2025 |
| Jefferies | David Windley | $393 | $287.85 | +5.0% | Nov 19, 2024 |
| Jefferies | David Windley | $536 | $413 | +43.3% | Feb 7, 2024 |
| Deutsche Bank | Analyst unavailable | $250 | $251.9 | -33.2% | Dec 14, 2022 |
| UBS | Analyst unavailable | $250 | $222.84 | -33.2% | Nov 30, 2022 |
Track every rating change on WST the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationWest Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies.…
Historical context
All WST earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
- CTASFY2027 Q1 · September 23, 2026+3.0% EPS-3.4% move
- PAYXFY2027 Q1 · September 23, 2026+1.5% EPS-8.8% move
- GISFY2027 Q1 · September 23, 2026+4.6% EPS+1.0% move
- AZOFY2026 Q4 · September 22, 2026+3.6% EPS+3.3% move
- FPSFY2026 Q4 · September 15, 2026+4.3% EPS+9.5% move
- TCOMFY2026 Q2 · September 15, 2026+22.3% EPS+3.0% move
Get the WST recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-09-24T18:10:56.171651+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-24T18:10:56.168727+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-09-24. For educational purposes only; not investment advice.